Objectives: Antifungal prophylaxis is recommended for haematological patients at high risk of invasive fungal infections (IFIs). Incidence, optimal therapeutic management and outcome of breakthrough IFIs (bIFIs) are largely unknown.
Introduction
Patients with long-term neutropenia following chemotherapy for AML and patients undergoing allogeneic HSCT are at high risk of contracting invasive fungal infections (IFIs). The clinical efficacy of antifungal prophylaxis in the prevention of IFIs in high-risk patients has been shown in randomized controlled trials and is now recommended in international guidelines. 1 -3 Consequently, routine application of antifungal prophylaxis for high-risk patients was implemented at our institution in 2006.
While the introduction of antifungal prophylaxis has reduced the number of IFIs and improved survival of high-risk patients, 4, 5 the management of breakthrough invasive fungal infections (bIFIs) has become a matter of concern. There is an ongoing debate on whether and to what extent antifungal prophylaxis changes the fungal spectrum towards rare and possibly more resistant species. 6 -8 In two retrospective observational studies, up to half of proven and probable bIFIs were caused by Mucorales or Fusarium spp. 6, 9 In contrast, two observational studies and two randomized trials on posaconazole prophylaxis reported no or only very few cases of bIFI by rare fungi. 4, 5, 10, 11 Taking this into account, treatment for bIFIs should be chosen wisely. Possible strategies include continuation of the ongoing prophylaxis, while controlling for factors impeding its efficacy, switch to an antifungal of the same class as the prophylaxis or switch of the antifungal class. The optimal approach remains unknown, since there are no studies investigating the clinical efficacy of different strategies for the treatment of bIFIs and data on the clinical epidemiology and outcome of bIFIs outside of clinical trials are scarce. Therefore, the present study aimed at assessing the frequency of bIFIs and the spectrum of causative pathogens, as well as the applied treatment modalities and associated outcomes.
Patients and methods

Study design
The aim of this study was to assess the frequency of bIFIs, as well as the associated causative pathogens, treatments and outcomes in patients receiving intensive chemotherapy for an AML or those undergoing allogeneic HSCT. The Cologne Cohort of Neutropenic Patients (CoCoNut), a noninterventional cohort study established in 1995 and assessing risk factors, interventions and outcomes of immunosuppressed patients with or without opportunistic infections (NCT01821456) was used to extract these data. This trial was initiated and designed by the academic authors.
Setting
All patients were diagnosed and treated according to local standards of care at the Department I of Internal Medicine of the University Hospital of Cologne. AML patients underwent remission-induction or consolidation chemotherapy regimens of the AML Cooperative Group (AML-CG), with high-dose cytarabine and anthracyclines being the most important cytotoxic treatments applied. In the years 2004 -05, AML patients received itraconazole or posaconazole as antifungal prophylaxis, whereas from 2006 onwards posaconazole was introduced as the standard antifungal prophylaxis. Protocols for conditioning chemotherapy in preparation for allogeneic HSCT comprised both myeloablative and reduced-intensity chemotherapy (RIC) regimens. In allogeneic HSCT patients, posaconazole prophylaxis was introduced in 2006, thus superseding itraconazole. From October 2009 onwards, the standard was adjusted to allow intermittent intravenous micafungin as bridging prophylaxis. 12 Micafungin was then initiated in patients unable to take oral medication, e.g. in cases of severe mucositis, nausea, severe diarrhoea and other conditions potentially impairing posaconazole exposure. In AML induction or consolidation therapy and allogeneic HSCT patients, posaconazole was exclusively administered as oral suspension.
Standard diagnostic procedures for patients at high risk of contracting IFI included galactomannan surveillance and two or more sets of blood cultures at onset of neutropenic fever, chest CTs after 72 -96 h of persistent fever and, in case of lung infiltrates, bronchoscopy with a bronchoalveolar lavage (BAL). All chest CT scans in the department are independently evaluated by radiologists and infectious disease specialists. Upon diagnosis of a lung infiltrate, the frequency of the galactomannan assay is intensified, and BAL specimens are analysed for the presence of galactomannan.
Inclusion and exclusion criteria
Database entries from January 2004 to April 2013 were screened. Patients were eligible for analysis if they had received systemically active antifungal prophylaxis for at least 4 days, either for induction or consolidation chemotherapy for AML with an expected time of neutropenia, defined as neutrophil counts ≤500/mL, of .7 days (AML cohort) or while undergoing allogeneic HSCT (HSCT cohort). Patients were only included once per group. We excluded patients receiving antifungal prophylaxis other than posaconazole, micafungin or itraconazole or any prophylactic agent as part of clinical trials, as well as those with an IFI diagnosed during a previous admission.
Documentation
In AML patients, occurrence of bIFI was assessed during each admission for induction or consolidation chemotherapy. Follow-up with regard to survival ended on day 365 after the first included admission or at death, whichever occurred first. In HSCT patients, bIFIs were assessed during hospitalization for conditioning chemotherapy and HSCT, as well as during all consecutive re-admissions within 365 days, in which antifungal prophylaxis was ongoing or resumed for the presence of severe graft-versus-host disease (GvHD; ≥grade II), requiring high-dose corticosteroids. Survival was followed until day 365 after transplantation or death, whichever occurred first.
Response to antifungal treatment was assessed on days 42 and 100 after diagnosis of bIFI.
Data capture included demographics, underlying disease, chemotherapeutic regimen given, type of transplant, information on mismatch status, cytomegalovirus (CMV) status of transplant donor and recipient, administration of immunosuppressants and antimicrobials, duration of neutropenia, incidence and duration of fever, occurrence and severity of GvHD, length of stay, results from microbiological and histopathological samples, azole plasma levels, results of CT imaging studies and survival. 
Definitions and data analysis
Possible, probable and proven bIFIs were defined according to the revised 2008 consensus criteria of the European Organization for Research and Treatment of Cancer/Infectious Disease Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG). 13 An index of ≥0.5 was defined as a positive galactomannan test in both serum and BAL fluid samples. The day of diagnosis was defined as the first day on which all necessary criteria were fulfilled. Response to treatment was assessed based on Segal et al. 14 The respective evaluation used both resolution of clinical signs and symptoms and computerized planimetry to estimate the percentage of change in bIFI lesions. The resolution of all clinical signs and symptoms and a reduction of lesions of .90% was defined as complete response. Clinical improvement and .50% reduction of lesions was defined as partial response. The absence of change from baseline or an improvement of ,50% was defined as stable response and progressive disease was defined as treatment failure.
14 Complete and partial responses were classified as successful outcomes, and stable responses and failures as unsuccessful outcomes. In contrast to Segal et al., 14 death during the observation period was not regarded as failure per se, but the response was assessed based on the last available clinical and imaging records. This way, deaths due to causes other than the IFI did not influence the classification of the bIFI-related response. To evaluate attributable mortality, we took into account the cause of death in the medical report, autopsy report or death certificate, as well as response to bIFI treatment.
The following endpoints were analysed using descriptive statistics: incidence of bIFI; spectrum of pathogens causing bIFI; treatment approaches; and response to treatment 14 and 42 days after diagnosis of bIFI. For patient characteristics and the endpoints lengths of stay and duration of neutropenia, differences between qualitative variables in the bIFI and non-bIFI groups were analysed by a x 2 test with continuity correction or Fisher's exact test where appropriate. Differences in quantitative variables were compared by t-test for independent samples. Outcome in relation to different treatment approaches was compared using Fisher's exact test. In a subgroup of patients contracting bIFI during posaconazole prophylaxis with available results of azole plasma levels, a receiver operating characteristic (ROC) analysis was performed to evaluate the last available plasma level measured within 2 -14 days prior to bIFI diagnosis as a group discriminator for first-line treatment. The optimal cut-off value for maximizing the product of sensitivity and specificity was determined. Furthermore, a log-rank test was performed to compare Kaplan -Meier survival estimates. A two-sided P value ,0.05 was considered significant.
Ethics statement
The CoCoNut is a non-interventional cohort in which data on risk factors, interventions and outcome of immunocompromised patients at risk of opportunistic infections are collected (NCT01821456). The CoCoNut has been approved by the local institutional review board and ethics committee (ID 13-108).
Results
Patients and admissions
A total of 708 AML patients with 2088 admissions and 512 HSCT patients with 694 admissions were identified in the database. After application of inclusion criteria, 250 AML patients with 329 admissions for induction or consolidation chemotherapy and 409 patients with their admissions for HSCT and 86 consecutive post-HSCT re-admissions due to GvHD or bIFI were included in the analysis. In the AML cohort, the median age was 55.5 years (IQR 18 years) in patients contracting a bIFI and 57 years (IQR 20 years) in those who did not (P ¼ 0.693). Furthermore, the slight difference in gender distribution, with 50.5% (96/190) female patients in non-bIFI cases and 40% (24/60) females in bIFI cases, was not statistically significant (P ¼ 0.183). The patient characteristics of HSCT patients are shown in Table 1 . In the HSCT cohort, age, gender, the distribution of underlying diseases, intensity of the conditioning regimen, donor type, CMV status, administration of immunosuppressives and occurrence of GvHD did not differ between bIFI and nonbIFI patients.
In the AML cohort, the length of stay during admissions for induction chemotherapy was significantly longer in bIFI patients (median 51 days) than in non-bIFI patients (median 42 days; P,0.001). The length of stay of admissions for consolidation chemotherapy did not differ significantly. Patients with bIFI during AML induction or consolidation therapy had a longer median duration of neutropenia (38 and 30 days) than non-bIFI patients (31 and 17 days; P,0.001). No significant differences in length of stay and duration of neutropenia were seen in HSCT patients with and without bIFI. Details on length of stay and duration of neutropenia in AML and HSCT cohorts are provided in Tables S1 and S2 (available as Supplementary data at JAC Online), respectively.
Antifungal prophylaxis
During the majority of hospitalizations in both cohorts, posaconazole was given as antifungal prophylaxis. In HSCT patients, posaconazole with micafungin bridging was the second most frequently observed prophylactic strategy, in both bIFI and non-bIFI admissions. In AML patients, administration of more than one antifungal for prophylaxis-usually given alternatelywas observed in only seven admissions. The distribution of prophylactic antifungals is shown in Table 2 .
Time to diagnosis, classification, localization and spectrum of bIFIs
In total, 60 patients (24.0%) in the AML cohort and 51 patients (12.5%) in the HSCT cohort contracted a bIFI during the included admissions. Of the 51 bIFIs in HSCT patients, 31 (60.8%) occurred during hospitalization for HSCT and 20 (39.2%) during post-HSCT re-admissions. The median time from first initiation of antifungal prophylaxis to diagnosis of bIFI was 19.5 days in AML patients The majority of bIFIs in both cohorts were possible bIFIs of the lungs. Probable bIFIs were all localized in the lungs as well, and mostly diagnosed by positive galactomannan in serum or BAL. Only in two probable bIFIs in the AML cohort did BAL diagnostics yield a positive culture, with Aspergillus niger and Aspergillus fumigatus, respectively. The proven cases in AML patients consisted of two fungaemia cases (Candida albicans and Fusarium spp.), two cases with histopathological findings indicative of Aspergillus spp. in resected lung tissue and one case with a combination of histopathological findings in resected lung and splenic abscess tissue indicative of Aspergillus species and growth of A. fumigatus in a BAL sample. The proven cases in HSCT patients included four fungaemia cases (two Candida glabrata, one Candida tropicalis and one C. albicans) and two cases with histopathological proof of mucormycosis. The respective findings were detected in hepatic, pulmonary and diaphragm tissue after resection in one case and in stomach and lung tissue during autopsy in the other case. Within probable and proven cases, results of susceptibility testing were available in overall three cases, all of which occurred during posaconazole prophylaxis: a fungaemia with C. albicans with increased MICs of fluconazole (.256 mg/L) and voriconazole (.32 mg/L), a fungaemia with C. glabrata that was determined to be intermediately susceptible to fluconazole (MIC 16 mg/L) and susceptible to voriconazole (MIC 0.25 mg/L) and a pulmonary bIFI with A. fumigatus detected in BAL with increased MICs of itraconazole (.16 mg/L), posaconazole (0.5 mg/L) and voriconazole (2 mg/L). In the last case, further molecular testing revealed a TR/L98H mutation in the cyp51A gene as the underlying mechanism of azole resistance. 15 Incidences of neutropenic fever, lung infiltrates associated with fever and classification of bIFIs are detailed in Table 3 .
Treatment and outcome of bIFIs
Regarding first-line treatment after diagnosis of bIFIs, continuation of the ongoing prophylactic antifungal was more frequent in HSCT patients (23/51; 45.1%) than in AML patients (20/60; 33.3%). While continuation of prophylaxis was more frequent in possible (18/44; 40.9%) than in probable and proven cases (2/16; 12.5%) in the AML cohort, the frequency was similar between possible (17/37; 45.9%) and probable and proven cases (6/14; 42.9%) in the HSCT cohort. Taking the complete treatment sequences into account, a high variability of approaches, including first-line treatments, second-line treatments and, in a few cases, third-line treatments, was observed. Treatment with liposomal amphotericin B was the most frequent treatment approach in AML patients (21/60; 35.0%), with an even higher proportion in probable and proven cases (8/16; 50.0%). The second most frequent approach was continuation of posaconazole (15/60; 25.0%). In HSCT patients, continuation of posaconazole (16/51; 31.4%) was the most frequent treatment approach, followed by a switch to caspofungin (10/51; 19.6%). The detailed frequencies of different treatment sequences in both cohorts are provided in Table S3 . Surgery of infected tissue was performed in four proven cases (three in the AML cohort and one in the HSCT cohort). In bIFI cases, prophylaxis was documented until the day of diagnosis of bIFI. Biehl et al. By using ROC analysis, a cut-off value was determined to predict the classification of each bIFI patient under posaconazole prophylaxis into either of the two first-line treatment groups (continuation versus switch). The cut-off value with the highest sensitivity (83.3%) and specificity (37.8%) was 0.498 mg/L. However, the AUC was 0.425, indicating an extremely weak prediction. The overall distribution of outcomes was similar between the two cohorts, with two-thirds of the bIFI patients (66.7% AML; 66.7% HSCT) having a successful outcome on day 100. In both cohorts, the rates of successful outcomes on days 42 and 100 were lower in probable and proven bIFI cases compared with possible bIFI. In AML patients with bIFI, 11 of 16 deaths (68.6%) within 100 days of diagnosis were regarded as attributable to bIFI. In HSCT patients, 12 of 16 deaths (75.0%) on day 100 after bIFI diagnosis were classified as attributable to bIFI. The outcome is shown in Table 4 .
In an explorative data analysis, the two most frequent approaches in first-line treatment, namely continuation of prophylaxis and switch of antifungal class, were compared regarding outcome on days 42 and 100 after diagnosis of bIFI. There were no statistically significant differences in the rates of successful outcome on days 42 and 100 and in the overall survival on days 42 and 100 between bIFI patients receiving continued prophylaxis and those receiving an antifungal of a different class as first-line treatment. Table 5 shows the respective rates regarding bIFI in the AML cohort, in the HSCT cohort and in both cohorts combined. The high variability in complete treatment sequences including second and third line did not allow comparison of associated outcome and survival.
Overall survival
Survival at day 365 after initiation of prophylaxis for non-bIFI and bIFI patients is shown in Figure 1 for the AML cohort (N ¼ 133, 70.0% versus N ¼ 38, 63.3%; P ¼ 0.297) and in Figure 2 for the HSCT cohort (N¼239, 66.8% versus N¼25, 49.0%; P ¼ 0.012). Fisher's exact test.
Breakthrough invasive fungal infections in high-risk patients
Discussion
To our knowledge, this is the largest published cohort study reporting real-life data on incidence, treatment and outcome of bIFI in patients receiving intensive chemotherapy for AML or undergoing an HSCT. bIFI occurred in 24.0% (60/250) of AML patients and 12.5% (51/409) of HSCT patients. Incidences of probable and proven bIFI were 6.4% (16/250) in AML patients and 3.4% (14/409) in HSCT patients. Previously, data on bIFI have been reported in the context of randomized trials and observational studies. Observed rates of probable and proven bIFI in randomized controlled trials assessing prophylaxis with posaconazole were rather low: 2% in AML patients and 5.3% in GvHD patients. 4, 5 However, observational studies on bIFI have reported rates comparable to our study, with incidences of possible bIFI ranging from 15% to 25% 10 and of probable and proven bIFI ranging from 3% to 13%. 6,9 -11,16,17 This range in the reported incidence of probable and proven bIFI may be explained by slight differences in the risk profile of patients receiving prophylaxis, by the minimum duration of prophylaxis, by differences in the implementation of invasive diagnostic procedures and by the availability of high-efficiency particulate air (HEPA) filtration. Furthermore, the availability and frequency of TDM at different sites may influence the frequency of bIFI.
The majority of patients in our cohort received posaconazole as the main prophylactic antifungal, partly with micafungin bridging. The rates of probable and proven bIFI (6.4% in AML and 3.4% in HSCT patients) were lower than rates from similar observational studies during fluconazole prophylaxis, with reported rates of 10.8% 18 and 17%. 19 Again, differences in study design limit the comparability of these observations. The superiority of posaconazole compared with both fluconazole and itraconazole was shown in randomized trials, with more marked differences in their controlled setting. 4, 5 Concerning the spectrum of fungi causing bIFI, it has been hypothesized that comprehensive implementation of broadspectrum antifungal prophylaxis has led to an increase in infections with rare fungi. 6, 17, 20 In our cohort, 3 of 11 proven cases and both of 2 culture-positive probable cases were caused by Aspergillus spp. Rare fungal infections, i.e. one fusariosis and two mucormycoses, constituted one-third of the 11 proven cases. In comparison, we previously reported on a historical cohort of 82 AML patients without systemic antifungal prophylaxis. In that group, there were no cases of fusariosis or mucormycosis among 16 proven or probable cases. 16 In a retrospective study from Austria, a pronounced increase in the proportion of bIFIs due to rare fungi was observed after the introduction of posaconazole prophylaxis. 6 While only 3 of 24 (13%) proven bIFIs in the historical cohort were caused by Mucorales and 14 (58%) by Aspergillus spp., 6 of 11 (55%) proven bIFIs were caused by Mucorales and none by Aspergillus spp. in the latter cohort. 6 In a recent study by Lerolle et al. 9 conducted in AML and HSCT patients, four of nine probable and proven bIFIs were caused by Mucorales or Fusarium spp. In another study in HSCT patients, one fusariosis and two rare yeasts (Trichosporon spp. and Geotrichum spp.) were observed in 23 probable and proven bIFI cases with otherwise non-rare fungi. 10 Despite methodological differences in these studies, e.g. in patients and prophylaxis under scrutiny, the findings suggest a certain proportional increase in rare fungi over the last decade. Obviously, broadspectrum antifungal prophylaxis decreases the rate of susceptible pathogens, such as Aspergillus spp. As a consequence, the proportion of bIFIs by rare and less susceptible fungi increases. An absolute increase in rare fungi is not evident, although it remains difficult to draw such conclusions from any of the available studies due to the overall low number of proven cases and differences in diagnostic procedures over time.
In our study, continuation of an ongoing prophylaxis was a frequent treatment approach, especially in HSCT patients. Even though there is no evidence from prospective trials on the optimal treatment of bIFI, guidelines generally recommend switching the antifungal class after diagnosis of bIFI. 21, 22 This approach is challenged by the fact that a high proportion of pathogens causing bIFI during posaconazole prophylaxis are tested susceptible to this broad-spectrum antifungal. 5, 6, 11 At least in some of these cases, the duration of prophylaxis until onset of bIFI may have been too short or there may have been conditions compromising serum levels of the prophylactic agent, such as malabsorption, interactions and poor compliance at the time of infection. 11, 20 We assessed the last available posaconazole plasma level within 2 -14 days prior to diagnosis of bIFI as a predictor of the choice of first-line treatment. There was a high range of observed levels, with a large overlap between patients receiving continued posaconazole as first-line treatment and those with a switch, impeding discrimination between the two groups by posaconazole levels. The corresponding ROC analysis failed to confirm posaconazole plasma levels as a predictor of a specific therapeutic decision.
In our explorative comparison of continuation of ongoing prophylaxis versus switch of the antifungal class as first-line treatment for bIFI, no difference regarding outcome on days 42 and 100 after diagnosis was seen. The absolute numbers even showed a slight advantage for continuation of prophylaxis. There was, however, a higher proportion of possible bIFIs in the group receiving continued prophylaxis, likely entailing a better outcome. This large proportion of patients with possible bIFIs remaining on prophylaxis may hint at the fact that these possible bIFIs had a different underlying aetiology.
Attributable mortality on day 100 was 18.3% (11/60) in AML patients with bIFI and 23.5% (12/51) in HSCT bIFI cases. We furthermore observed a decreased overall survival in bIFI patients, which was statistically significant in the HSCT cohort. This finding may suggest an influence of bIFI on overall survival of HSCT patients; nevertheless, the underlying analysis does not control for other variables that might have had an impact on survival; e.g. the presence of GvHD after HSCT is associated with both increased rates of bIFI and decreased overall survival.
As a limitation of our study, the inclusion criterion of a minimum of 4 days of antifungal prophylaxis may be considered very short. We chose this duration to allow comparison with previous data from previous observations 6 and because steady-state plasma levels are usually reached by day 5. However, it cannot be ruled out that some of the reported bIFIs were actually present before initiation of antifungal prophylaxis.
In summary, this large cohort study in patients receiving induction or consolidation chemotherapy for AML and those undergoing HSCT demonstrates that bIFIs remain a rare, but potentially lifethreatening complication in times of established antifungal prophylaxis. Rare fungal species should be expected in these patients, although reported proportions differ widely. We observed a high variability of applied treatment approaches, with continuation of the prophylactic treatment being a frequently reported choice. Further studies are needed to evaluate associated outcomes for different treatment approaches and thus optimize management of bIFIs in high-risk patients.
